<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04730375</url>
  </required_header>
  <id_info>
    <org_study_id>AP2007-50109</org_study_id>
    <nct_id>NCT04730375</nct_id>
  </id_info>
  <brief_title>Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients</brief_title>
  <official_title>Evaluation of the Effect of Different Doses Dexmedetomidine Infusion on Lung Mechanics and Oxygenation in Obese Patients Undergoing Laparoscopic Cancer Surgeries: A Randomized Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Institute, Egypt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute, Egypt</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      • The objective of this study is to evaluate the effect of different doses of dexmedetomidine&#xD;
      infusion intraoperative on lung mechanics and oxygenation regarding PaO2/Fraction of inspired&#xD;
      oxygen), Intraoperative oxygenation, lung compliance (static and dynamic), dead space, and&#xD;
      PaCO2,heart rate, mean arterial blood pressure in obese patients undergoing laparoscopic&#xD;
      cancer surgeries&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Dexmedetomidine is a selective agonist of α2receptorswhose tendency to α2 receptors is eight&#xD;
      times more than that of clonidine. It also has powerful sedative, analgesic,&#xD;
      anti-inﬂammatory, and organ protective properties. dexmedetomidine has favorable respiratory&#xD;
      effects in humans. The effects of dexmedetomidine on oxygenation and lung mechanics had been&#xD;
      investigated in obstructive lung disease. Dexmedetomidine decreased dead space and improved&#xD;
      both lung compliance and oxygenation in chronic obstructive pulmonary disease (COPD) patients&#xD;
      undergoing lung cancer surgery. Morbidly obese patients are characterized by the high&#xD;
      prevalence of restrictive lung disease.The study include 2 equal groups, each group is 35&#xD;
      patients: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of&#xD;
      (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery and&#xD;
      Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg&#xD;
      LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">February 2021</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">May 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>The study include 2 equal groups, each group is 35 patients: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery and Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Care Provider)</masking>
    <masking_description>Randomization is done using computer generated sequence. Concealment will be achieved by opaque envelope</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Oxygenation by the end study drug infusion</measure>
    <time_frame>baseline and end of surgery</time_frame>
    <description>P/F ratio: PaO2/Fraction of inspired oxygen</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung compliance</measure>
    <time_frame>baseline and end of surgery</time_frame>
    <description>static and dynamic</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Obesity; Drug</condition>
  <arm_group>
    <arm_group_label>( Group A)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>: Group A(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (1μg/Kg LBW) bolus, followed by 0.5μg/Kg/hour continuous infusion till the end of surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>(Group B)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Group B(N=35) dexmedetomidine is infused intraoperative after intubation at dose of (0.5μg/Kg LBW) bolus, followed by 0.3μg/Kg/hour continuous infusion till the end of surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexmedetomidine Injection [Precedex]</intervention_name>
    <description>two different doses dexmedetomidine bolus then maintenance infusion till end of surgeries and evaluation of lung mechanics and oxygenation</description>
    <arm_group_label>( Group A)</arm_group_label>
    <arm_group_label>(Group B)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18-60years&#xD;
&#xD;
          -  Obese patients BMI&gt;25 Kg/meter square&#xD;
&#xD;
          -  Patients undergoing laparoscopic cancer surgery.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Heart failure&#xD;
&#xD;
          -  Arrhythmias&#xD;
&#xD;
          -  Severe liver or kidney impairment&#xD;
&#xD;
          -  Patients with forced expiratory volume in 1 sec (FEV1)/FVC &lt; 70%&#xD;
&#xD;
          -  Heart block&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mohamed abdel wadod, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Institute (NCI)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Mohamed Abdel wadod, MD</last_name>
    <phone>+201006645981</phone>
    <email>m_wadod@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Nataional Cancer Instituite</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>mohamed Abdel Wadod, MD</last_name>
      <phone>+201006645981</phone>
      <email>m_wadod@yahoo.coll</email>
    </contact>
    <contact_backup>
      <last_name>mohammed Elsayed, MD</last_name>
      <phone>+20100921645</phone>
    </contact_backup>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>January 26, 2021</study_first_submitted>
  <study_first_submitted_qc>January 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2021</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cancer Institute, Egypt</investigator_affiliation>
    <investigator_full_name>Mohammed Abdelfattah Abdelwadod</investigator_full_name>
    <investigator_title>Mohammed Abdelfattah Abdelwadod</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

